Pharma Mar S.A.
4 products tracked · names used in filings: Pharma Mar S.A.
Upcoming milestones
No upcoming milestones listed.
Recent milestones
Fri 29 May 2026🇪🇺 EU approval (EC decision)
Zepzelca (lurbinectedin) approved in the EU
Marketing authorisation to Pharma Mar S.A.; Orphan, Additional monitoring · source
Thu 26 Mar 2026🇪🇺 CHMP positive opinion
Zepzelca (lurbinectedin): CHMP positive opinion
Pharma Mar S.A.; Orphan, Additional monitoring · source
Products
| Product | Status | Approved | |
|---|---|---|---|
| 🇪🇺 | Aplidin plitidepsin | Application withdrawn | |
| 🇪🇺 | Yondelis trabectedin | Refused | |
| 🇪🇺 | Zepzelca lurbinectedin | Authorised | 2026-05-29 |
| 🇪🇺 | Yondelis trabectedin | Authorised | 2007-09-17 |
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.